Conditions: Gastroesophageal Reflux Disease
Keywords: GERD lesogaberan impedance pH pharmacokinetics safety tolerability
Allocation: RANDOMIZED | Intervention model: CROSSOVER
Enrollment: 27
Healthy volunteers: no

Brief summary:
The purpose of the study is to estimate what effect 4 different doses of AZD3355 will have on the number of reflux episodes, in patients who have GERD and still experience symptoms despite proton pump inhibitor (PPI) treatment.

Detailed description:

Arms:
arm 1: AZD3355 30 mg arm 2: AZD3355 90 mg arm 3: AZD3355 120 mg arm 4: AZD3355 240 mg arm 5: Placebo

Interventions: intervention 1: AZD3355 intervention 2: AZD3355 intervention 3: AZD3355 intervention 4: AZD3355 intervention 5: placebo
Intervention descriptions: intervention 1: 30 mg orally in the morning and 30 mg in the evening for 1 day intervention 2: 90 mg orally in the morning and 90 mg in the evening for 1 day intervention 3: 120 mg orally in the morning and 120 mg in the evening for 1 day intervention 4: 240 mg orally in the morning and 240 mg in the evening for 1 day intervention 5: Placebo capsules orally in the morning and placebo capsules in the evening for 1 day

Protocol document: